Isotope Labeling-Driven Glycomics: Advancing Early Colorectal Cancer Biomarker Discovery

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. A major clinical challenge lies in the fact that most patients are diagnosed at advanced stages, where survival rates drop dramatically. Traditional diagnostic biomarkers such as carcinoembryonic antigen (CEA) and CA19-9 suffer from limited sensitivity and specificity, making them inadequate for early-stage screening. To address this unmet need, the study introduces a novel glycomics-based strategy that leverages isotope labeling and high-resolution mass spectrometry to identify more reliable biomarkers for early CRC detection ^[1].

Fig. 1. Overview of this study.

Innovative Methodology

The core innovation of this research lies in the integration of three advanced technologies:

• Pronase E digestion for non-specific glycan release
• 3-benzoyl/(benzoyl-2,3,4,5,6-d5)-2-oxothiazolidine-4-carboxylic acid (d0/d5-BOTC) isotope labeling tags glycans at the reducing end for relative quantification
• UHPLC-Q-Orbitrap HRMS for high-resolution detection

Unlike traditional enzymes such as PNGase F, pronase E enables broader glycan release, including both N- and O-linked glycans, while maintaining structural integrity. Meanwhile, the d0/d5-BOTC probe specifically labels the reducing end of released glycans. After glycoproteins are enzymatically digested, glycans are liberated with a free aldehyde group at their reducing terminus. The BOTC reagent reacts with this aldehyde via oxime formation, resulting in stable covalent attachment. By labeling two different sample groups (e.g., healthy vs. CRC) with d0 and d5 variants, the glycans become chemically identical but mass-shifted, allowing them to be distinguished in mass spectrometry.

This workflow significantly enhances both sensitivity and throughput, making it suitable for large-scale clinical biomarker screening.

Fig. 2. d 0/d5-BOTC-labeled serum and tissue glycan derivatives examined using HPLC-Q-Orbitrap HRMS.

Experimental Design

The study analyzed:

• 102 serum samples (51 healthy controls, 51 CRC patients)
• 90 tissue samples (45 cancerous, 45 paracancerous)

CRC cases included stage II and stage III patients, ensuring relevance to early and intermediate disease progression. Glycans were extracted, labeled, and analyzed using a newly constructed database of 331 glycan derivatives, enabling robust identification and quantification. This dual-sample approach (serum + tissue) provides a more comprehensive understanding of glycan alterations and improves biomarker reliability.

Key Findings: Identification of High-Performance Glycan Biomarkers

Through isotope labeling-enabled analysis, the study identifies four key glycan biomarkers:

These glycans showed statistically significant differences between CRC patients and healthy individuals (P < 0.01). Importantly, their diagnostic performance surpassed conventional biomarkers:

• AUC values ranged from 0.68 to 0.91
• Diagnostic accuracy reached up to 91%
• Sensitivity exceeded that of CEA, with H4N5F1SA achieving >90% sensitivity

Additionally, H5N4F demonstrated consistent downregulation in both serum and tissue samples, indicating strong disease specificity and making it a particularly promising biomarker.

Biological Insights: Mechanisms Behind Glycan Alterations

The quantitative power of isotope labeling allows deeper biological insights:

• Increased sialylation (e.g., H5N4F3SA) is associated with overexpression of sialyltransferases (ST6GAL1, ST3GAL4)
• Altered fucosylation patterns result from abnormal activity of fucosyltransferases (FUT3, FUT6, FUT8)

These molecular changes reflect tumor-associated glycosylation remodeling, which plays a critical role in cancer progression and immune evasion. Such mechanistic insights not only validate the biomarkers but also highlight potential therapeutic targets.

Clinical Implications: Toward Non-Invasive Early Diagnosis

The study highlights the clinical potential of isotope labeling-based glycomics:

• Enables serum-based (non-invasive) diagnostics
• Provides higher sensitivity for early-stage detection
• Supports standardization across laboratories

Unlike conventional assays, isotope labeling offers reproducible quantification, making it more suitable for translation into clinical workflows. As a result, this approach represents a major step toward practical, high-accuracy CRC screening tools.

Reference

[1] Li Y., et al. Screening of glycan biomarkers for early detection of colorectal cancer based on novel isotope labeling relative quantitative method [J]. Journal of Pharmaceutical Analysis, 2025: 101262.

Online Inquiry



mg g kg ml L

Isotope Labeling-Driven Glycomics: Advancing Early Colorectal Cancer Biomarker Discovery

SUBMIT